Palau vs Post-demographic dividend: Prevalence of hypertension
Palau
44.2%
in 2019
Post-demographic dividend
31.5%
in 2019
Palau rank
33rd
Post-demographic dividend rank
35th
Prevalence of hypertension over time
- Palau
- Post-demographic dividend
How they compare
Palau currently reports 44.2% against 31.5% in Post-demographic dividend, a difference of 12.7%.
That makes Palau's figure about 1.4 times Post-demographic dividend's.
Across all 30 years both countries report, Palau has been ahead every year.
Palau ranks 33rd and Post-demographic dividend ranks 35th of 192 countries.
Palau has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Palau | Post-demographic dividend | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 39.9% | 37.2% | 2.7% | Palau |
| 2000s | 41.9% | 35.0% | 6.9% | Palau |
| 2010s | 44.2% | 32.6% | 11.6% | Palau |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hypertension, Palau or Post-demographic dividend?
- Palau, at 44.2% against 31.5% in Post-demographic dividend as of 2019.
- What is the difference in prevalence of hypertension between Palau and Post-demographic dividend?
- 12.7%, with Palau ahead.
- How many years of comparable data are there for Palau and Post-demographic dividend?
- 30 years are reported by both, from 1990 to 2019.
- How do Palau and Post-demographic dividend rank globally for prevalence of hypertension?
- Palau ranks 33rd and Post-demographic dividend ranks 35th of 192 countries.
- Where does this data come from?
- World Health Organization's Global Health Observatory Data Repository, published as Prevalence of hypertension (% of adults ages 30-79). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Prevalence of hypertension is the percentage of adults ages 30-79 with hypertension (defined as having systolic blood pressure =140 mmHg, diastolic blood pressure =90 mmHg, or taking medication for hypertension). The data is age-standardized.